Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies

References

• Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk of relapse associated with T-cell depletion. Ann Int Med 1988;108:806–14.
   Google Scholar
• Collins RH, Shpilberg 0, Drobyski WR et al. Donor leuko-cyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. 7 Clin Oncol 1997;15: 433–44.
   Google Scholar
• Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog contain-ing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:12–20.
   Google Scholar
• Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmal-ignant hematologic diseases. Blood 1998;91:756–63.
   PubMed Web of Science ®Google Scholar
• Carella AM, Lerma E, Corsetti MT et al. Evidence of cyto-genetic and molecular remission by allogeneic cells after imunosuppressive therapy alone. Br 7 Haematol 1998; 103:565–7.
   PubMed Web of Science ®Google Scholar
• Khouri IF, Keating M, Körbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine based nonablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies. y Clin Oncol 1998;16:2817–24.
   PubMed Web of Science ®Google Scholar
• Childs R, Epperson D, Bahçeci E et al. Molecular remission of chronic myeloid leukaemia following a non-myeloabla-tive allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect. Br yHaemato11999;107:396–400.
   PubMed Web of Science ®Google Scholar
• Xun CQ, Thompson JS, Jennings CD et al. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994;83:2360–7.
   PubMed Web of Science ®Google Scholar
• Grigg A, Bardy P, Byron K et al. Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukemia and lym-phoma. Bone Marrow Transplant 1999;23:107–10.
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Wagner JL, Maloney DG et al. Outpatient PBSC allografts using immunosuppression with low dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood1998;92(Suppl 1):519a.
   Google Scholar
• Milpied N, Coste-Burel M, Accard F et al. Epstein—Barr virus associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 1999;23:629–30.
   PubMed Web of Science ®Google Scholar
• Nagler A, Panigrahi S, Varadi G et al. Invasive fungal infec-tions following reduced conditioning for matched allogeneic stem cell transplantation (alloSCT). Bone Marrow Transplant 2000;25 (Suppl 1):S129.
   Google Scholar
• Vaz CP, Campos A, Campilho F et al. Non-myeloablative conditioning regimen in allogeneic peripheral blood stem cell transplantation (alloPBSCT) for high risk hematologic malignancies — preliminary results. Bone Marrow Transplant 2000;25 (Suppl 1):S133.
   Google Scholar
• Bacigalupo A, Vitale V, Corvo R et al. The combined effect of total body irradiation (TB!) and cyclosporine A (CsA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. Br Haematol 2000;108:99–104.
   PubMed Web of Science ®Google Scholar
• Kottaridis PD, Chakraverty R, Milligan DW et al. A non-myeloablative regimen for allogeneic stem cell transplantation with a low incidence of GvHD. Bone Marrow Transplant 2000;25 (Suppl 1):S26.
   Google Scholar
• Kelemen E, Masszi T, Remenyi P et al Reduction in the fre-quency of transplant-related complications in patients with chronic myeloid leukaemia undergoing BMT precondi-tioned with a new, non-myeloablative drug combination. Bone Marrow Transplant 1998; 21:747–9.
   Google Scholar
• Sykes M, Preffer F, McAfee S et al. Mixed lympho-haematopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mis-matched bone marrow transplantation. Lancet 1999;353: 1755–9.
   PubMed Web of Science ®Google Scholar
• Gomez-Almaguer D, Ruiz-Arguelles GJ, Ruiz Arguelle A et al. Hematopoietic stem cell allografts using a nonmyeloab-lative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant 2000;25(2):131–3.
   Google Scholar
• Dazzi F, Sztdio RM, Craddock C et al. Comparison of sin-gle dose and escalating dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukaemia. Blood 2000;95:67–71.
   PubMed Web of Science ®Google Scholar
• Fuchs EJ, Seber A, Altomonte V et al. Chemotherapy does not nullify the ability of donor lymphocyte infusions to mediate graft-versus-host reactions. Bone Marrow Transplant 1998;22:303–5.
   Google Scholar